Knowledge of new developments in melanoma care in the last year are crucial to appropriate management of melanoma patients. The new 8th Edition American Joint Committee on Cancer (AJCC) staging has made significant changes to melanoma staging, especially for stage III patients, and enabled better determination of prognosis. The results of Multicentre Selective Lymphadenectomy Trial II which randomised sentinel node positive patients to completion dissection versus observation and also the results of several adjuvant drug trials for high risk melanoma patients have also been released. These trial results have changed the treatment paradigm for melanoma patients.
Dermatology Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia 11 Hobart Medical Specialist, Hobart, Tasmania, Australia Introduction: Optimal biopsy of a lesion that is suspicious for melanoma is crucial for diagnosis, planning definitive treatment, staging and prognostication. The increasing use of punch and shave biopsies can lead to incorrect diagnosis, tumour base transection and loss of prognostic information. We summarise the systematic review, evidence, recommendations and practice points from new national guidelines for the biopsy of suspected melanomas.
Main Recommendations: Complete excision with a 2 mm margin is the most reliable diagnostic biopsy method for pigmented skin lesions suspected of being melanoma. Partial biopsies may not be fully representative of the lesion and should be avoided unless there are sound clinical reasons to utilise them. Partial biopsies need to be interpreted with caution and in light of clinical findings, to minimise false negative diagnosis and underestimation of staging.
Other Important Recommendations: Despite the recommendations of previous Australian and other clinical practice guidelines, there is evidence of inappropriate overuse of shave or deep shave (saucerisation) biopsy of invasive melanomas, leading to excessive rates of base transection and interference with the definitive assessment of tumour thickness, the most important prognostic indicator. Punch biopsies of part of an atypical melanocytic lesion should be used with extreme caution for the diagnosis of melanoma because of higher rates of false negative pathological diagnosis. Over the past decade there has been an explosion of information on the potential genetic mutations contributing to melanoma development. It will be increasingly important that clinical dermatologists are aware of these, the indications for screening, and how to interpret all this information for patients.
Candidate germline genes include those associated with pigmentation (MC1R), those associated with DNA repair (CDKN2A, BAP1) and those associated with naevus count (IRF4). There has also been many studies into somatic mutations in the actual melanoma tissue, which have been harnessed in designing novel treatments for melanoma.
We report the findings of phenotypic analysis along with whole exome sequencing in a cohort of 225 multiple melanoma patients from Brisbane, Australia. Major findings include significantly higher rates of MC1R mutation in this cohort (62%) versus controls (25%). The MCIR mutation rate in patients with a history of an amelanotic melanoma was 80%. CDKN2A mutation rate in patients under 40 years of age was 17.4%, significantly higher than the normal population at 1.3%. We also report the findings of pedigree analysis in this cohort, and whether than has a positive predictive value for known genetic mutations.
Lentigo maligna and lentigo maligna melanoma characteristics, management and evolution: A 10-year retrospective study H. Australia and New Zealand share the highest incidence rates of melanoma worldwide. Despite the substantial increase in public and physician awareness of melanoma in Australia over the last 30 years -as a result of the introduction of publicly funded mass media campaigns that began in the early 1980s -mortality has steadily increased during this period. This increased mortality has led investigators to question the relative merits of primary versus secondary prevention; that is, sensible sun exposure practices versus early detection. Here I address the issue of secondary prevention of melanoma with respect to incidence and mortality (and cost per life saved) by developing a Markov model of melanoma epidemiology based on Australian incidence and mortality data. I show that the surveillance enhancement that began in 1982 has resulted in greater diagnostic incidence and reduced mortality, but the reduced mortality carried a significant cost per life saved. I implement the model out to 2028 and demonstrate that the enhanced secondary prevention that began in 1982 becomes increasingly cost-effective over the period 2013-2028. Given the ballooning costs of increased melanoma surveillance, I suggest the process of public health policy decision-making -particularly with respect to the public funding of melanoma screening and discretionary mole removal -would be better served by incorporating the results of quantitative modelling.
ASN 002 genetically modified adenovirus therapy in the treatment of nodular basal cell carcinoma G. Siller Central Brisbane Dermatology, Brisbane, Queensland, Australia
Intra tumoural injections of gamma interferon into basal cell carcinoma has been demonstrated to result in clearance between 50 to 90%. Results of a trial utilising ASN 002, a recombinant human adenovirus expressing gamma interferon for nodular basal carcinoma, in both sporadic and basal cell naevus syndrome will be presented. The novel mechanism of action and immunopathogenesis of response will be discussed.
Update on the continuing benefits of the dermatologyradiation oncology collaboration 
